EUVIMEDObjevte EUVIMED
Open access · CC BY-NC 4.0

Comparing drug combinations for graft-versus-host disease prophylaxis using the U.S. Food and Drug Administration Adverse Event Reporting System

Toru Ogura iD, Chihiro Shiraishi iD, Aiko Urawa iD

Clinical Transplantation and Research · 2025-06-30 · 39 (2) · 131-141

DOI: 10.4285/ctr.24.0049 ↗

At a glance

Journal article in Clinical Transplantation and Research, published online on 2025-04-15. Written by Toru Ogura and 2 co-authors. Institution: Clinical Research Support Center, Mie University Hospital, Tsu, Japan. Cited 2 times so far (Crossref); 30 references. The full text is freely available (open access, CC BY-NC 4.0).

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Graft-versus-host disease (GVHD) is a severe complication for transplant patients, particularly those undergoing allogeneic hematopoietic stem cell transplantation. Although various GVHD prophylaxis drug combinations are administered in clinical settings, previous studies have primarily focused on monotherapies or limited drug combinations.

Methods

We analyzed data from the U.S. Food and Drug Administration Adverse Event Reporting System for patients receiving GVHD prophylaxis drugs between January 2004 and March 2024. Efficacy was evaluated based on the recorded occurrence or nonoccurrence of GVHD following the administration of prophylactic drugs. Drug combinations were compared using the reporting odds ratio (ROR) and adjusted ROR (aROR), which were calculated through univariate and multivariate binomial logistic regression analyses, respectively. The aROR controlled for differences in patient backgrounds.

Results

This study identified 10 GVHD prophylaxis drug combinations with aROR values significantly less than 1, indicating high effectiveness, and 13 combinations with aROR values significantly greater than 1, representing low effectiveness.

Conclusions

The results demonstrated that certain GVHD prophylaxis drug combinations, particularly those including cyclosporine, may be relatively ineffective. However, avoiding cyclosporine is not always feasible in clinical settings, where treatment plans must be tailored to each patient. To address this issue, the study also identified cyclosporine-containing drug combinations that exhibit high efficacy. These findings could help inform the development of personalized treatment strategies for GVHD prophylaxis and thus improve outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation.

Subjects

Author keywords

CyclosporineGraft vs host diseaseHematopoietic stem cell transplantationPersonalized medicinePharmacovigilance

Authors and institutions

  • Clinical Research Support Center, Mie University Hospital, Tsu, Japan.
  • Department of Pharmacy, Mie University Hospital, Tsu, Japan.
  • Organ Transplantation Center, Mie University Hospital, Tsu, Japan.

ORCID profiles: Toru Ogura, Chihiro Shiraishi, Aiko Urawa

Cite

APA

Ogura, T., Shiraishi, C., & Urawa, A. (2025). Comparing drug combinations for graft-versus-host disease prophylaxis using the U.S. Food and Drug Administration Adverse Event Reporting System. Clinical Transplantation and Research, 39(2), 131-141. https://doi.org/10.4285/ctr.24.0049

Vancouver

Ogura T, Shiraishi C, Urawa A. Comparing drug combinations for graft-versus-host disease prophylaxis using the U.S. Food and Drug Administration Adverse Event Reporting System. Clinical Transplantation and Research. 2025;39(2):131-141. doi:10.4285/ctr.24.0049

BibTeX
@article{Ogura2025,
  author = {Ogura, Toru and Shiraishi, Chihiro and Urawa, Aiko},
  title = {Comparing drug combinations for graft-versus-host disease prophylaxis using the U.S. Food and Drug Administration Adverse Event Reporting System},
  journal = {Clinical Transplantation and Research},
  year = {2025},
  volume = {39},
  number = {2},
  pages = {131--141},
  doi = {10.4285/ctr.24.0049}
}
Start for free →